1 / 10

Cutaneous T-cell lymphoma Market

Cutaneous T-Cell Lymphoma is a group of lympho -proliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL).<br>

Download Presentation

Cutaneous T-cell lymphoma Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cutaneous T-cell Lymphoma (CTCL) Cutaneous T-Cell Lymphoma is a group of lympho-proliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas are common types of skin lymphoma. More than three out of every four skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body. • 1 • 2 • 3 • 4 There are different subtypes of CTCL. Most are slow growing, but some can be fast growing. The most common types of CTCL are Mycosis Fungoides and Sezary Syndrome. The men accounts for over 53% of the total cases of CTCL. The occurrence of CTCL in men had been higher than in women. • DelveInsight © 2019 | All rights reserved

  2. CTCL Epidemiology The higher Cutaneous T-cell Lymphoma incident cases was 3312 in 2017 in the United States, followed by EU5 and Japan. Cutaneous T-cell Lymphoma total incident population in the seven major markets (7MM) was estimated to be 8557 cases in 2017. CTCL prevalence Allergic Conjunctivitis CTCL PREVALENCE CTCL prevalence UK had the highest CTCL incident population followed by Germany in 2017 whereas Spain had the lowest incident population. Japan had 1276 Cutaneous T-Cell Lymphoma cases. CTCLPREVALENCE There were 1290 early stage and 664 late-stage Cutaneous T-cell Lymphoma patients in the United States in 2017. • DelveInsight © 2019 | All rights reserved

  3. Cutaneous T-cell Lymphoma Market There are different therapies available for CTCL treatment, but some of the therapies lead to adverse events. Bexarotene is an oral retinoid therapy that is effective for the treatment of early- and advanced- stage CTCL. Cutaneous T-Cell Lymphoma market size is estimated to be USD 703.68 million in 2017 in the seven major markets (7MM)*. The United States accounted for the largest CTCL market size. Among the EU5 countries, the UK had the highest market size in 2017, while Spain had the lowest CTCL market size. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. Research is undergoing to develop targeted and more specific therapies for CTCL treatment. Antifolate inhibitors, agents are currently being evaluated in patients. * 7MM- USA, EU-5(Germany, Spain, Italy, France and UK), Japan • DelveInsight © 2019 | All rights reserved

  4. CTCL Emerging Drugs and Companies 01 Drug- SGX301 Company- Soligenix 02 Drug- Quisinostat Company- Janssen 03 Drug- Remetinostat Company- Medivir AB 04 Drug- Resminostat Company- 4SC AG • DelveInsight © 2019 | All rights reserved

  5. Complete Information For complete information on Cutaneous T-cell Lymphoma Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  6. About DelveInsight Mission 2 1 3 About To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. Vision DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved

  7. Services by DelveInsight PharmDelve Forecasting OpportunityAssessment Consulting ReportStore MarketIntelligence Competitive Analysis Pipeline • DelveInsight © 2019 | All rights reserved

  8. Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved

  9. Pompe Disease 9

More Related